Cover Image
市場調查報告書

缺血再灌流傷害:開發平台分析

Ischemia Reperfusion Injury - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253658
出版日期 內容資訊 英文 167 Pages
訂單完成後即時交付
價格
Back to Top
缺血再灌流傷害:開發平台分析 Ischemia Reperfusion Injury - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 167 Pages
簡介

再灌流傷害,是指持續缺血或氧不足的狀態後,由於再度開始供給組織血液而發生的組織傷害。由於缺血狀態時,沒供給血液氧和營養,就算血液循環恢復,正常功能的回復引起氧化壓,也帶來發炎和氧化損傷的結果。治療中,包含抗氧化療法,抗白血球療法,抗補體療法等。

本報告提供缺血再灌流傷害的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

缺血再灌流傷害概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

各調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

各調查中的產品:各大學/研究機關

開發治療藥的企業

  • Amyndas Pharmaceuticals LLC
  • Angion Biomedica Corp.
  • Antipodean Pharmaceuticals, Inc.
  • Bayer AG
  • Biomedica Management Corporation
  • Bolder Biotechnology, Inc.
  • Curatis Pharma GmbH
  • Ensemble Therapeutics Corporation
  • Erimos Pharmaceuticals, LLC
  • Gilead Sciences, Inc.
  • Ischemix, Inc.
  • 興和
  • LG Life Science LTD.
  • Magnus Life Science
  • NeuroVive Pharmaceutical AB
  • Nyken B.V.
  • Omeros Corporation
  • Opsona Therapeutics Limited
  • Orexo AB
  • Pharming Group N.V.
  • PledPharma AB
  • Prolong Pharmaceuticals
  • Proteo, Inc.
  • Prothix BV
  • Stealth BioTherapeutics Inc.
  • Zealand Pharma A/S

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AER-271
  • AM/AMBP-1
  • ANV-6L15
  • APP-103
  • BAY-606583
  • BB-3
  • BBT-059
  • bucillamine
  • C1 人類酯酶阻礙因子
  • CMX-2043
  • CRX-526
  • Curaglutide
  • danegaptide
  • Des-Asp Angiotensin 1
  • 缺血再灌流傷害 用ADAM17抑制劑
  • EP-80317
  • GS-459679
  • KN-93
  • LH-021
  • mangafodipir trisodium
  • MG-53
  • mirococept
  • MitoQ
  • 缺血再灌流傷害的單株抗體
  • 循環系統疾病、腎臟移植、腫瘤學 的CD47阻礙單株抗體
  • 腎性缺血再灌流傷害 的IL-16阻礙單株抗體
  • MTP-131
  • NBD 肽
  • NecX
  • Neutrolide
  • NP-202
  • NVP-019
  • NYK-1112
  • 腫瘤學、心臟血管的寡核甘酸
  • OMS-721
  • OPN-305
  • PAC-G31P
  • PIN-201601
  • pitavastatin NP
  • PMC-6
  • PRO-02
  • R-190
  • 缺血再灌流傷害、心肌缺血的 FPR2活性組換形式肽
  • 敗血症、發炎性腸道疾病、急性腎臟損傷、急性輻射症候群、缺血性內臟器官損傷的組換形式蛋白質
  • 缺血再灌流傷害、血栓症的 Robo1 工作組換形式蛋白質Slit2
  • 胰炎、循環系統、免疫學的 CXCL阻礙組換形式蛋白質
  • 缺血再灌流傷害、低氧症的組換形式蛋白質
  • 缺血再灌流傷害的 PTCH1 工作組換形式蛋白質
  • 心肌病、缺血再灌流傷害的白細胞介素-1受體較量組換形式蛋白質
  • Sanguinate
  • 再灌流傷害、心臟病發作的小分子
  • 再灌流傷害的δ類鴉片物質促效劑
  • 心肌缺血、缺血再灌流傷害的精胺酸酶1、2阻礙小分子
  • 缺血再灌流傷害的小分子
  • 缺血再灌流傷害、發炎性疾病的小分子
  • 缺血再灌流傷害的 SGK-1活性小分子
  • 缺血再灌流傷害、老年癡呆症的親環蛋白 D 阻礙小分子
  • 循環系統疾病的 PDE5阻礙小分子
  • 缺血再灌流傷害的合成肽
  • 腫瘤學、免疫學、循環系統傷害的合成肽
  • terameprocol
  • tiomolibdate diammonium
  • tiprelestat
  • TMS-007
  • UCF-101
  • UWA-TAT

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8318IDB

Summary

Global Markets Direct's, 'Ischemia Reperfusion Injury - Pipeline Review, H2 2016', provides an overview of the Ischemia Reperfusion Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
  • The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects
  • The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ischemia Reperfusion Injury Overview
  • Therapeutics Development
    • Pipeline Products for Ischemia Reperfusion Injury - Overview
    • Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis
  • Ischemia Reperfusion Injury - Therapeutics under Development by Companies
  • Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes
  • Ischemia Reperfusion Injury - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ischemia Reperfusion Injury - Products under Development by Companies
  • Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes
  • Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
    • Amyndas Pharmaceuticals LLC
    • Angion Biomedica Corp.
    • Biomedica Management Corporation
    • Bolder Biotechnology, Inc.
    • Corline Biomedical AB
    • Curatis Pharma GmbH
    • Erimos Pharmaceuticals, LLC
    • Gilead Sciences, Inc.
    • Ischemix, Inc.
    • Kowa Company, Ltd.
    • LG Life Science LTD.
    • Omeros Corporation
    • Opsona Therapeutics Limited
    • Orexo AB
    • Pharming Group N.V.
    • PledPharma AB
    • Prolong Pharmaceuticals, LLC
    • Proteo, Inc.
    • Prothix BV
    • Recordati S.p.A.
    • Stealth BioTherapeutics Inc.
  • Ischemia Reperfusion Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AER-271 - Drug Profile
    • AM/AMBP-1 - Drug Profile
    • ANV-6L15 - Drug Profile
    • APP-103 - Drug Profile
    • BB-3 - Drug Profile
    • BBT-059 - Drug Profile
    • C1 esterase inhibitor (recombinant) - Drug Profile
    • CMX-2043 - Drug Profile
    • CRX-526 - Drug Profile
    • Curaglutide - Drug Profile
    • Des-Asp Angiotensin 1 - Drug Profile
    • Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile
    • elamipretide - Drug Profile
    • EP-80317 - Drug Profile
    • GS-459679 - Drug Profile
    • hemin (human) - Drug Profile
    • KN-93 - Drug Profile
    • LH-021 - Drug Profile
    • mangafodipir trisodium - Drug Profile
    • MG-53 - Drug Profile
    • mirococept - Drug Profile
    • Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile
    • Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile
    • Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation - Drug Profile
    • Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile
    • NecX - Drug Profile
    • Neutrolide - Drug Profile
    • NP-202 - Drug Profile
    • Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile
    • OMS-721 - Drug Profile
    • OPN-305 - Drug Profile
    • pitavastatin NP - Drug Profile
    • PRO-02 - Drug Profile
    • R-190 - Drug Profile
    • Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile
    • Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
    • Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
    • Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile
    • Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
    • Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile
    • Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile
    • Renaparin - Drug Profile
    • Sanguinate - Drug Profile
    • Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile
    • Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
    • Small Molecules for Ischemia Reperfusion Injury - Drug Profile
    • Small Molecules for Ischemia Reperfusion Injury - Drug Profile
    • Small Molecules for Ischemia Reperfusion Injury - Drug Profile
    • Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile
    • Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile
    • Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile
    • Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
    • Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile
    • Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile
    • terameprocol - Drug Profile
    • tiprelestat - Drug Profile
    • TMS-007 - Drug Profile
    • UCF-101 - Drug Profile
    • UWA-TAT - Drug Profile
    • VCP-746 - Drug Profile
  • Ischemia Reperfusion Injury - Dormant Projects
  • Ischemia Reperfusion Injury - Discontinued Products
  • Ischemia Reperfusion Injury - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ischemia Reperfusion Injury, H2 2016
  • Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Ischemix, Inc., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Orexo AB, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Recordati S.p.A., H2 2016
  • Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ischemia Reperfusion Injury - Dormant Projects, H2 2016
  • Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H2 2016
  • Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H2 2016
  • Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H2 2016
  • Ischemia Reperfusion Injury - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ischemia Reperfusion Injury, H2 2016
  • Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top